文献速递血液净化与透析水电解质与酸碱

蔗糖氢氧化氧铁在腹膜透析患者中的一年疗效与安全性

One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该研究为多中心3期开放标签随机对照试验的亚组分析,纳入84例腹膜透析患者,比较蔗糖氢氧化氧铁与司维拉姆治疗52周的效果。结果显示蔗糖氢氧化氧铁在降血磷方面非劣于司维拉姆,且药片负担更低、依从性更高。

要点

  • 蔗糖氢氧化氧铁降血磷效果非劣于司维拉姆,52周时达标率分别为62.5%和64.3%。
  • 蔗糖氢氧化氧铁药片负担更低(3.4±1.3 vs 8.1±3.7片/天),依从性更高(91.2% vs 79.3%)。
  • 两组不良事件以胃肠道反应为主,蔗糖氢氧化氧铁组发生率为86.0%,司维拉姆组为93.1%。

核心结论

  • 在腹膜透析患者中,蔗糖氢氧化氧铁控制血磷非劣于司维拉姆,且药片负担相对较低、依从性高。

研究设计与样本

  • 多中心、3期、开放标签、随机(2:1)、活性对照试验(NCT01324128及其扩展NCT01464190)的亚组分析,共纳入1055例透析患者中的84例腹膜透析患者(蔗糖氢氧化氧铁组56例,司维拉姆组28例),治疗52周。

主要发现

  • 第12周时两组血磷浓度较基线平均下降0.6 mmol/L。
  • 52周内蔗糖氢氧化氧铁降血磷效果与司维拉姆相似,分别有62.5%和64.3%的患者达到KDOQI目标范围(≤1.78 mmol/L)。
  • 蔗糖氢氧化氧铁组药片负担为3.4±1.3片/天,司维拉姆组为8.1±3.7片/天。
  • 治疗依从率蔗糖氢氧化氧铁组为91.2%,司维拉姆组为79.3%。
  • 至少发生一次治疗中出现的不良事件的比例:蔗糖氢氧化氧铁组86.0%,司维拉姆组93.1%;两组最常见不良事件均为胃肠道反应,蔗糖氢氧化氧铁组为腹泻和粪便变色,司维拉姆组为恶心、呕吐和便秘。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sucroferric oxyhydroxide is a noncalcium, iron-based phosphate binder that demonstrated sustained serum phosphorus control, good tolerability and lower pill burden compared with sevelamer carbonate (sevelamer) in a Phase 3 study conducted in dialysis patients. This subanalysis examines the efficacy and tolerability of sucroferric oxyhydroxide and sevelamer in the peritoneal dialysis (PD) patient population. METHODS: The initial study (NCT01324128) and its extension (NCT01464190) were multicenter, Phase 3, open-label, randomized (2:1), active-controlled trials comparing sucroferric oxyhydroxide (1.0-3.0 g/day) with sevelamer (2.4-14.4 g/day) in dialysis patients over 52 weeks in total. RESULTS: In the overall study, 84/1055 (8.1%) patients received PD and were eligible for efficacy analysis (sucroferric oxyhydroxide, n = 56; sevelamer, n = 28). The two groups were broadly comparable to each other and to the overall study population. Serum phosphorus concentrations decreased comparably with both phosphate binders by week 12 (mean change from baseline - 0.6 mmol/L). Over 52 weeks, sucroferric oxyhydroxide effectively reduced serum phosphorus concentrations to a similar extent as sevelamer; 62.5% and 64.3% of patients, respectively, were below the Kidney Disease Outcomes Quality Initiative target range (≤1.78 mmol/L). This was achieved with a lower pill burden (3.4 ± 1.3 versus 8.1 ± 3.7 tablets/day) with sucroferric oxyhydroxide compared with sevelamer. Treatment adherence rates were 91.2% with sucroferric oxyhydroxide and 79.3% with sevelamer. The proportion of patients reporting at least one treatment-emergent adverse event was 86.0% with sucroferric oxyhydroxide and 93.1% with sevelamer. The most common adverse events with both treatments were gastrointestinal: diarrhea and discolored feces with sucroferric oxyhydroxide and nausea, vomiting and constipation with sevelamer. CONCLUSIONS: Sucroferric oxyhydroxide is noninferior to sevelamer for controlling serum phosphorus in patients undergoing PD, while providing a relatively low pill burden and a high rate of adherence.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Floege J, Covic AC, Ketteler M, et al. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. Nephrol Dial Transplant. 2017. PMID: 28339993. doi:10.1093/ndt/gfw460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。